July 02, 2025

Body Fat Percentage Outranks BMI for Mortality

New research shows body fat percentage predicts long-term mortality more accurately than BMI, suggesting a need to revise how body composition is measured in clinical care.

Conexiant

June 30, 2025

Can Typos Change a Diagnosis?

Large language models used in clinical decision-making may offer different treatment recommendations depending on how a patient writes their message—even when the medical facts remain unchanged.

Conexiant

June 27, 2025

Weight Loss Drugs, Heavier Implications

New guidance positions GLP-1 and GLP-1/GIP therapies as frontline options for long-term weight management—with profound implications for cardiovascular outcomes, access equity, and chronic disease care.

Conexiant

June 25, 2025

Nighttime Heart Rhythms Predict Brain Disorders

A large Swiss study found that nighttime heart rate patterns may predict future risk for brain and psychiatric disorders, while traditional sleep structure measures were less informative.

Conexiant

June 23, 2025

Sitting-Rising Test Predicts Long-Term Mortality Risk

A 12-year study of over 4,000 adults found that poor performance on a basic sitting and rising test was strongly linked to increased risk of death from natural and cardiovascular causes.

Conexiant

June 19, 2025

Single Psilocybin Dose Yields Long-Term Cancer Relief

A single psilocybin dose combined with therapy led to lasting reductions in depression and anxiety for cancer patients two years after treatment, according to new research.

Conexiant

June 18, 2025

Dream Recall Tied to Sleep Style

A new study of over 200 adults links dream recall to specific sleep patterns and mental traits such as mind wandering, highlighting how age, interference, and seasonal changes affect whether dreams are remembered.

Conexiant

June 16, 2025

Short, Insufficient Sleep Tied to Anxiety

A study found that both short sleep duration and insufficient sleep perception were linked to higher risks of anxiety and fatigue but not depression.

Conexiant

June 16, 2025

Cytisinicline Shows Efficacy In Smoking Cessation Trial 

A phase 3 randomized clinical trial found that cytisinicline, a partial agonist at α4β2 nicotinic acetylcholine receptors, improved smoking cessation rates compared with placebo, with higher abstinence rates and reduced craving over 24 weeks.

Conexiant